Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

7Total
Not Applicable (1)
P 2 (6)

Trial Status

Unknown3
Recruiting2
Not Yet Recruiting1
Terminated1

Clinical Trials (7)

Showing 7 of 7 trials
NCT06850103Phase 2Recruiting

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases

NCT05731726Phase 2RecruitingPrimary

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

NCT05733611Phase 2Terminated

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

NCT07374809Not ApplicableNot Yet Recruiting

IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER

NCT04659382Phase 2Unknown

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

NCT04483219Phase 2Unknown

Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

NCT04527068Phase 2Unknown

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Showing all 7 trials

Research Network

Activity Timeline